Abstract:Abstract Phenotypic and functional heterogeneity is one of the hallmarks of human cancers. Tumor genotype variations among tumors within different patients are known as interpatient heterogeneity, and variability among multiple tumors of the same type arising in the same patient is referred to as intra-patient heterogeneity. Subpopulations of cancer cells with distinct phenotypic and molecular features within a tumor are called intratumor heterogeneity (ITH). Since Nowell proposed the clonal evolution of tumor cell populations in 1976, tumor heterogeneity, especially ITH, was actively studied. Research has focused on the genetic basis of cancer, particularly mutational activation of oncogenes or inactivation of tumor-suppressor genes (TSGs). The phenomenon of ITH is commonly explained by Darwinian-like clonal evolution of a single tumor. Despite the monoclonal origin of most cancers, new clones arise during tumor progression due to the continuous acquisition of mutations. It is clear that disruption of the "epigenetic machinery" plays an important role in cancer development. Aberrant epigenetic changes occur more frequently than gene mutations in human cancers. The epigenome is at the intersection of the environment and genome. Epigenetic dysregulation occurs in the earliest stage of cancer. The current trend of epigenetic therapy is to use epigenetic drugs to reverse and/or delay future resistance to cancer therapies. A majority of cancer therapies fail to achieve durable responses, which is often attributed to ITH. Epigenetic therapy may reverse drug resistance in heterogeneous cancer. Complete understanding of genetic and epigenetic heterogeneity may assist in designing combinations of targeted therapies based on molecular information extracted from individual tumors.

Cellular Heterogeneity and Molecular Evolution in Cancer

Heterogeneity in Primary Tumors and Corresponding Metastases: Could It Provide Us with Any Hints to Personalize Cancer Therapy?

Investigating intratumour heterogeneity by single-cell sequencing.

Clinical implications of intratumor heterogeneity: challenges and opportunities

Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis

Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future

Using Single‐cell Multiple Omics Approaches to Resolve Tumor Heterogeneity

Molecular heterogeneity in breast cancer: State of the science and implications for patient care

Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma

Deciphering intratumoral heterogeneity using integrated clonal tracking and single-cell transcriptome analyses

Intratumoral Heterogeneity of Hepatocellular Carcinoma: from Single-Cell to Population-Based Studies

Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung Cancer

Biological Significance of Tumor Heterogeneity in Esophageal Squamous Cell Carcinoma

A Richer Understanding of Intratumoral Heterogeneity: Single-Cell Genomics Put It Within Reach

Systems Heterogeneity: an Integrative Way to Understand Cancer Heterogeneity.

Heterogeneity of the tumor immune microenvironment and its clinical relevance

Clonal Heterogeneity and Tumor Evolution in Liver Cancer: the Cutting Edge and the Future

Tumour heterogeneity and resistance to cancer therapies

Epigenetic Heterogeneity in Cancer

Epigenomic heterogeneity as a source of tumour evolution

Translating Cancer Molecular Variability into Personalized Information Using Bulk and Single Cell Approaches